ZenBio

ZenBio is a long-established provider of critical biological research tools and contract services, with a core focus on human adipocytes and stem cells for regenerative medicine and cosmetics applications. The company has built a reputation for high-quality, consistent cell-based products and has recently expanded its capabilities into exosome and extracellular vesicle therapeutics, as evidenced by multiple awarded SBIR grants. In August 2024, ZenBio was acquired by BioIVT, a strategic move that integrates it into a larger global research model provider, enhancing its distribution and service reach while continuing its independent research programs.

Platform for isolation, culture, and application of primary human cells (especially adipocytes and stem cells) and development of tuned stem cell-derived extracellular vesicles/exosomes for therapeutic use.

In research tools/services, ZenBio competes with large life science suppliers (e.g., Thermo Fisher, Lonza) and niche primary cell providers. In the emerging exosome/EV therapeutic space, it faces competition from a growing number of biotech startups and academic spin-outs, all vying to overcome significant scientific and manufacturing hurdles.